2 results
Approved WMOCompleted
Primary ObjectivesTo assess the safety of 2 fixed doses of EVP-6124 (2 or 3 mg daily) for up to 52 weeks in subjects withAlzheimer*s disease (AD) who complete (Day 182) studies EVP-6124-024 or EVP-6124-025Secondary ObjectivesTo assess the duration…
Approved WMORecruiting
The main purpose of this pilot study is to assess the feasibility and potential efficacy of implant retained mandibular advancement device (MAD) therapy on a small scale in edentulous patients with mild to moderate OSA in terms of sleep apnea…